# EDGAR Filing Document

**Accession Number:** 0001819790
**File Stem:** 0001819790-25-000088
**Filing Date:** 2025-6
**Character Count:** 7429
**Document Hash:** bc1086f078716d69154968ac25b2c278
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001819790-25-000088.hdr.sgml**: 20250616

**ACCESSION NUMBER**: 0001819790-25-000088

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250612

**FILED AS OF DATE**: 20250616

**DATE AS OF CHANGE**: 20250616

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** LINK WILLIAM J PHD
- **CENTRAL INDEX KEY:** 0001228684

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39614
- **FILM NUMBER:** 251050002

**MAIL ADDRESS:**
- **STREET 1:** ONE SANSOME STREET
- **STREET 2:** SUITE 1650
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94104
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tarsus Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001819790
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 814717861
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 15440 LAGUNA CANYON ROAD
- **CITY:** IRVINE
- **STATE:** CA
- **ZIP:** 92618
- **BUSINESS PHONE:** (949) 409-9820

**MAIL ADDRESS:**
- **STREET 1:** 15440 LAGUNA CANYON ROAD
- **CITY:** IRVINE
- **STATE:** CA
- **ZIP:** 92618

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>LINK WILLIAM J PHD<br><sub>(Last) (First) (Middle)</sub><br>C/O TARSUS PHARMACEUTICALS, INC.<br>15440 LAGUNA CANYON ROAD, SUITE 160<br><sub>(Street)</sub><br>IRVINE, CA 92618<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-06-12 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Tarsus Pharmaceuticals, Inc. [ TARS ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-06-13 |  | M<sup>(1)</sup> |  | 3350 | A | <sup>(1)</sup> | 170448 | D |  |
| Common Stock |  |  |  |  |  |  |  | 10446 | I | By Link Family Enterprise, LP<sup>(2)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (right to buy) | $40.95 | 2025-06-12 |  | A |  | 4540 |  | <sup>(3)</sup> | 2035-06-11 | Common Stock | 4540 | $0 | 4540 | D |  |
| Restricted Stock Units | <sup>(4)</sup> | 2025-06-12 |  | A |  | 2954 |  | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 2954 | $0 | 2954 | D |  |
| Restricted Stock Units | <sup>(4)</sup> | 2025-06-13 |  | M |  |  | 3350 | <sup>(6)</sup> | <sup>(6)</sup> | Common Stock | 3350 | $0 | 0 | D |  |

---

### Footnotes:

(1) The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

(2) The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Link Family Enterprise, LP.

(3) Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

(4) Each RSU represents a contingent right to receive one share of the Company's common stock.

(5) RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

(6) RSUs granted on June 13, 2024, in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employeedirector's continuous service.

**Signature:** /s/ Scott Sieckert, Attorney-in-Fact  
**Date:** 2025-06-16

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**